Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral MGCD265 Administered With Interruption to Subjects with Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2015
At a glance
- Drugs Glesatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors MethylGene
- 16 Nov 2011 Actual patient number (47) added as reported in a MethylGene media release.
- 14 Nov 2011 Primary endpoint 'Maximum-tolerated-dose' has been met.
- 14 Nov 2011 Results presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, as reported in a MethylGene media release.